Retatrutide + Follistatin 344 Blend
Combined weight-management and lean-mass support.
$445
A combination of the triple-agonist peptide Retatrutide and the myostatin-inhibiting Follistatin 344, studied for compounded weight-management and lean-mass research.
- Retatrutide: GLP-1/GIP/glucagon triple-agonist research on weight and metabolism.
- Follistatin 344: myostatin inhibition supporting lean-mass research.
- Together: explored for combined fat-loss and muscle-preservation research.
1
Dosing schedule
Concentration
10.4 mg/ml, total 3 ml (30mg Reta + 1.2mg Follistatin), total 31.2mg
Frequency
Once a week
Dose
As per protocol
Duration
6 Months
Break
6 Months
Investigational — not approved by the FDA. Weekly dosing studied in most protocols.
For research use only. Not for human consumption. Not evaluated by the FDA.